| 1 |
34551970 | Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma. | 2022 Feb |
1 |
| 2 |
35330879 | In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma. | 2022 |
1 |
| 3 |
35331723 | Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia. | 2022 May 5 |
1 |
| 4 |
33296710 | Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. | 2021 Mar 1 |
2 |
| 5 |
33721621 | Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. | 2021 Apr |
4 |
| 6 |
33923880 | Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib. | 2021 Apr 20 |
2 |
| 7 |
33929994 | Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. | 2021 Oct 1 |
2 |
| 8 |
34981062 | Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice. | 2021 Dec 20 |
2 |
| 9 |
32336008 | A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. | 2020 Aug |
1 |
| 10 |
32800552 | Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma. | 2020 Oct 20 |
4 |
| 11 |
30860683 | Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro. | 2019 Feb |
1 |
| 12 |
31233590 | Vandetanib photoinduced cutaneous toxicities. | 2019 May |
1 |
| 13 |
31299389 | Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. | 2019 Sep |
3 |
| 14 |
29363191 | Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography. | 2018 Jun |
2 |
| 15 |
29517106 | Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. | 2018 May |
1 |
| 16 |
30321910 | Epidermal growth factor receptor blockers for the treatment of ovarian cancer. | 2018 Oct 16 |
1 |
| 17 |
30555244 | Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells. | 2018 |
2 |
| 18 |
26986978 | Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. | 2017 Aug |
1 |
| 19 |
28132823 | Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. | 2017 Apr 1 |
2 |
| 20 |
28259610 | Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. | 2017 Apr |
1 |
| 21 |
25352401 | Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. | 2016 Mar |
2 |
| 22 |
26832794 | EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib. | 2016 Mar |
3 |
| 23 |
27250896 | Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer. | 2016 May |
1 |
| 24 |
27711083 | RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt. | 2016 Nov 8 |
1 |
| 25 |
27798882 | The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer. | 2016 Oct |
2 |
| 26 |
27983649 | Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia. | 2016 Dec 14 |
2 |
| 27 |
25503302 | Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. | 2015 Feb |
1 |
| 28 |
25887790 | Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. | 2015 Apr 3 |
2 |
| 29 |
25910950 | A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. | 2015 Aug 15 |
1 |
| 30 |
26050198 | ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. | 2015 Aug 28 |
3 |
| 31 |
26170630 | Selective use of vandetanib in the treatment of thyroid cancer. | 2015 |
1 |
| 32 |
24412287 | Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. | 2014 Oct |
1 |
| 33 |
24502390 | Vandetanib for the treatment of thyroid cancer: an update. | 2014 Mar |
1 |
| 34 |
24671507 | A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. | 2014 Aug |
1 |
| 35 |
24709487 | Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. | 2014 Jun |
1 |
| 36 |
24924416 | Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. | 2014 Jul |
1 |
| 37 |
25057173 | EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. | 2014 Oct |
5 |
| 38 |
25089348 | Vandetanib as a potential treatment for breast cancer. | 2014 Sep |
1 |
| 39 |
25117183 | Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. | 2014 Sep |
2 |
| 40 |
22608542 | Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. | 2013 Nov |
1 |
| 41 |
23177099 | Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials. | 2013 Jan |
1 |
| 42 |
23202050 | Vandetanib and the management of advanced medullary thyroid cancer. | 2013 Jan |
1 |
| 43 |
23231950 | Vandetanib for the treatment of medullary thyroid cancer. | 2013 Feb 1 |
3 |
| 44 |
23274758 | Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. | 2013 Feb 15 |
4 |
| 45 |
23487538 | Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. | 2013 Jun |
1 |
| 46 |
23584298 | Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. | 2013 May |
3 |
| 47 |
23640345 | Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. | 2013 May 15 |
1 |
| 48 |
23799852 | Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. | 2013 Jul 9 |
2 |
| 49 |
24005613 | Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). | 2013 Dec |
1 |
| 50 |
21046425 | Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents. | 2012 Apr |
1 |